Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15809 | 1.00 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL9430673 | 1.00 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL29430977 | 1.00 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL6517023 | 1.00 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL6744970 | 1.00 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL9717057 | 0.97 | STAT3 (0.41) | STAT3STAT1 | |
| SCHEMBL21729 | 0.97 | STAT3 (0.41) | STAT3STAT1 | |
| SCHEMBL1603039 | 0.97 | STAT3 (0.41) | STAT3STAT1 | |
| SCHEMBL705768 | 0.97 | STAT3 (0.41) | STAT3STAT1 | |
| SCHEMBL1572838 | 0.97 | STAT3 (0.41) | STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577250-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | Abdera Therapeutics Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. | 2025-02-13 | — | — | US | disclosed |
| US-20240207462-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (CA) | 2024-06-27 | — | — | US | disclosed |
| WO-2024044551-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051476-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | DLK1, DBNL, DVL3 | STAT3 3056/4885STAT1 2497/4885 |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | DLK1, CD2BP2, IGLV6-57 | STAT3 3120/4885STAT1 2759/4885 |
| US-20240207462-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | FCGR2A, FCGR3B, CD74 | STAT3 3389/4885STAT1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.